CAFs are not targeted by paclitaxel, whereas bioactive PAs (1)–(4) maintain dose-dependent anti-proliferative effects presumably by blocking NFκB and HIF signaling and reducing tumor-promoting CAF activation. This evidence concerns the gene NFKB1 and neoplasm.